

Table S2: Summary of PolyPEPI1018-induced immune responses based on measured IVS ELISpot assay results

Immunological responses	Number of patients % (n/N)
CD8⁺ T cell responses	
Pre-existing	70% (7/10)
<i>De novo</i>	80% (8/10)
Post-vaccination (boosted + <i>de novo</i>)	90% (9/10)
Against ≥ 3 TAAs	80% (8/10)
CD4⁺ T cell responses	
Pre-existing	100 % (10/10)
Post-vaccination	100% (10/10)
CD8⁺ and CD4⁺ T cell responses	90% (9/10)
TAA: Tumor-associated antigen targeted by the vaccine; pre-existing: detected before vaccination; <i>de novo</i> : detected only after vaccination; boosted: at least two-fold increase in magnitude compared to pre-vaccination T cell responses. Related to Figure 3A and B.	